Skip to main content
Japan Tissue Engineering Co., Ltd. logo

Japan Tissue Engineering Co., Ltd. — Investor Relations & Filings

Ticker · 7774 ISIN · JP3389610001 T Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2022-08-10 Interim / Quarterly Rep…
Country JP Japan
Listing T 7774

About Japan Tissue Engineering Co., Ltd.

https://www.jpte.co.jp/en/

Japan Tissue Engineering Co., Ltd. (J-TEC) is a company focused on the commercialization and industrialization of regenerative medicine. It develops, manufactures, and sells tissue-engineered medical products. The company operates through three primary business segments: the Regenerative Medicine Business, which provides its own therapeutic products such as autologous cultured cartilage and epidermis; the Custom Development & Manufacturing (CDMO) Business, offering contract services to support other developers in the field; and the LabCyte Business, which supplies cultured human tissue models for research and safety assessment purposes. J-TEC aims to establish regenerative medicine as a standard of care in healthcare.

Recent filings

Filing Released Lang Actions
四半期報告書－第25期第1四半期(令和4年4月1日－令和4年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Japan Tissue Engineering Co., Ltd., covering the first quarter of the 25th fiscal year (April 1, 2022, to June 30, 2022). It contains detailed financial statements, management analysis, and business status updates, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2022-08-10 Japanese
内部統制報告書－第24期(令和3年4月1日－令和4年3月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the framework, scope, and results of the company's internal controls over financial reporting. Since this is a standalone regulatory report regarding internal control systems and audit-related compliance rather than a full annual report (10-K) or a simple announcement, it falls under the 'Audit Report / Information' category.
2022-06-16 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1, in Japan. This is a mandatory document accompanying the Annual Securities Report (Yukashoken Hokokusho) to confirm the accuracy of the report's contents. Since it is a regulatory filing required by law to accompany the annual report but is not the annual report itself, and does not fit into other specific categories like 'Audit Report' or 'Management Report', it falls under the 'Regulatory Filings' (RNS) category. FY 2022
2022-06-16 Japanese
有価証券報告書－第24期(令和3年4月1日－令和4年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains detailed financial statements, business history, management indicators, and regulatory disclosures required by the Financial Instruments and Exchange Act. It is a comprehensive annual filing, not an announcement or a summary. FY 2022
2022-06-16 Japanese
四半期報告書－第24期第3四半期(令和3年10月1日－令和3年12月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter of the 24th fiscal period, filed by Japan Tissue Engineering Co., Ltd. with the Tokai Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis, and business status updates for the period ending December 31, 2021. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-02-14 Japanese
四半期報告書－第24期第2四半期(令和3年7月1日－令和3年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Tokai Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MDA), and business performance data for the second quarter of the fiscal year ending March 31, 2022. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2021-11-12 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.